摘要
目的系统评价棕榈酸帕利哌酮注射液(Paliperidone Palmitate,PP)治疗精神分裂症药物经济学特性。方法系统检索PubMed、Embase、Cochrane Library、Sciencedirect和中国知网(China National Knowledge Infrastructure,CNKI)、万方数据库(Wanfang)、中国生物医学文献数据库(China Biology Medicine,CBM)等数据库,根据标准筛选文献,并使用卫生经济学评价报告规范(Consolidated Health Economic Evaluation Reporting Standards,CHEERS)量表进行质量评价,对研究结果进行系统性分析。结果共纳入13项研究,CHEERS量表得分范围为17～23.5分,平均(20.35±1.84)分,优秀率达到61.54%。文献采用了决策树模型或Markov模型并进行了成本-效果、成本-效用或成本-效益等分析。结果表明使用PP依从性更高,复发率更低,且其增量成本效果比(Incremental cost-effectiveness ratio,ICER)低于意愿支付阈值;PP均能获得较高的质量调整生命年(Quality-adjusted life years,QALY),且ICER均低于意愿支付阈值。单因素分析和概率敏感性分析均表示经济学研究结果稳定。结论棕榈酸帕利哌酮注射液治疗精神分裂症急性期和稳定期的维持治疗具有良好的经济学优势。
Objective To systematically evaluate the pharmacoeconomic characteristics of paliperidone palmitate （PP） injection in the treatment of schizophrenia. Methods The system retrieved databases such as PubMed, Embase, Cochrane Library, Sciencedirect and China National Knowledge Infrastructure（CNKI）, Wanfang database, and China Biology Medicine（CBM）. The literature was screened according to the criteria and the Consolidated Health Economic Evaluation Reporting Standards （CHEERS） scale was used for quality evaluation. Systematic analysis was carried out for the results of the study. Results A total of 13 studies were included. The CHEERS scale scored from 17 points to 23.5 points, with an average score of 20.35±1.84 and an excellent rate of 61.54%. The literature adopted a decision tree model or a Markov model and performed cost-effectiveness, cost-utility, or cost-benefit analysis. The results showed that PP compliance was higher and the recurrence rate was lower, and its incremental cost-effectiveness ratio （ICER） was lower than the willingness payment threshold; PP could achieve a higher quality-adjusted life years（QALY）, and ICER was lower than the willingness payment threshold. Both univariate analysis and probabilistic sensitivity analysis indicated that the economic research results were stable. Conclusion Paliperidone palmitate injection has a good economic advantage in the treatment of acute schizophrenia and in the maintenance treatment of stable schizophrenia.
作者
周义湘
张苏菡
崔志强
陈雪丽
黄颖华
ZHOU Yixiang;ZHANG Suhan;CUI Zhiqiang;CHEN Xueli;HUANG Yinghua(Department of Pharmacology,Xiamen Xianyue Hospital,Xiamen 361012,China)
出处
《中国现代医生》
2018年第31期95-99,103,共6页
China Modern Doctor
关键词
棕榈酸帕利哌酮
系统评价
精神分裂症
药物经济学
Paliperidone palmitate （PP）
Systematic evaluation
Schizophrenia
Pharmacoeconomics
